Clinical Rheumatology

, Volume 30, Issue 2, pp 269–273

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis

Authors

  • Yang Mei
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Jing Gao
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Rui Ge
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Zhenhua Duan
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Zhen Zeng
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Fangfang Liao
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Guo Xia
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Sheng Wang
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
  • Shengqian Xu
    • Department of Rheumatology, First Affiliated hospitalAnhui Medical University
  • Jianhua Xu
    • Department of Rheumatology, First Affiliated hospitalAnhui Medical University
  • Li Zhang
    • Anhui Medical Genetics Center in Anhui Medical College
  • Dongqing Ye
    • Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical University
Brief Report

DOI: 10.1007/s10067-010-1647-4

Cite this article as:
Mei, Y., Pan, F., Gao, J. et al. Clin Rheumatol (2011) 30: 269. doi:10.1007/s10067-010-1647-4

Abstract

Interleukin 17 (IL-17) is a Th17 cytokine associated with inflammation, autoimmunity, and defense against some bacteria; it has been implicated in many chronic autoimmune diseases including psoriasis, multiple sclerosis, and systemic sclerosis. However, whether IL-17 plays a role in the pathogenesis of ankylosing spondylitis (AS) remains unclear. To analyze the content of IL-17 and IL-23 in the serum from patients with AS compared with health control subject, 50 patients with AS and 43 healthy volunteers were recruited. Serum IL-17 levels were examined by enzyme linked immunosorbent assay (ELISA). Statistic analyses were performed by SPSS 13.0. Results show that the serum IL-17 and IL-23 levels were significantly elevated in AS patients as compared with normal controls. Nevertheless, no associations of serum IL-17 and IL-23 levels with clinical and laboratory parameters were found; no significant difference regarding serum IL-17 and IL-23 levels was found between less active AS and more active AS. However, there was a strong positive association between the serum levels of IL-17 and IL-23 in the AS patients. Our results indicate increased serum IL-17 and IL-23 levels in AS patients, suggesting that this two cytokine may play critical roles in the pathogenesis of AS. Therefore, further studies are required to confirm this preliminary data.

Keywords

Ankylosing spondylitisInterleukin 17Interleukin 23

Copyright information

© Clinical Rheumatology 2010